Natco Pharma Limited is a vertically integrated and R&D focused pharmaceutical company engaged in developing, manufacturing and marketing of finished dosage formulations (“FDF”) and active pharmaceutical ingredients (“APIs”). Our focus is primarily on niche therapeutic areas and complex products. We market and distribute our products in over 40 countries. We sell our FDF products in the United States, India, Europe and the rest of the world (“RoW”). We also operate in certain key geographies through our subsidiaries.
We manufacture API products which are primarily used for captive consumption in our FDF products and are also sold to customers for various international markets such as Brazil, Europe and USA. In the API segment, we have capabilities to develop and manufacture products with multi-step synthesis, semi synthetic fusion technologies, high-potency APIs and peptides.
We are also engaged in contract manufacturing business, whereby we undertake selected contracts with pharmaceutical companies to manufacture and supply pharmaceutical products.
NATCO’s domestic oncology division deals with haemato-oncology and solid tumor products.
NATCO has over 30 years of expertise in formulating innovative dosage forms. NATCO today is leveraging on this expertise to go global by exporting finished dosage products Read More
The launch of a generic version of long-awaited complex blockbuster drug, Glatiramer Acetate in the USA market has catapulted the company to the next orbit in terms of its capability and credibility as a niche player in pharmaceutical sector. Read More
Natco has proven technical and operational expertise of over two decades in developing and commercialising niche APIs. Our unwavering commitment to quality; cGMP compliance to deliver affordable drug substances with novelty Read More
Natco is well recognized as a high quality contract manufacturing company to many leading pharmaceutical firms in India. This is supported at Natco by its high inclination towards quality systems and state-of-the-art facilities Read More